NLRP3 and hepatocellular carcinoma: However, compared with non-tumor samples, some PRGs with CNV gain, including NLRP3, were significantly downregulated in HCC (p < 0.01); some PRGs with CNV loss, including CASP3, were significantly upregulated in HCC (p < 0.001).